Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00490425
Other study ID # JHGU-195/02
Secondary ID
Status Completed
Phase Phase 4
First received June 21, 2007
Last updated June 21, 2007
Start date October 2002
Est. completion date October 2006

Study information

Verified date June 2007
Source Johann Wolfgang Goethe University Hospitals
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

Given that asthma results from a complex interaction between genetic susceptibility and environmental factors and rates of childhood asthma are increasing, primary prevention has to focus on modifiable aspects such as nutrition. There a implications from epidemiology that food supplementation with probiotics given to atopic mothers in pregnancy and during lactation can prevent the development allergies in the offspring. Children with atopic dermatitis are at increased risk (up to 80%) of developing persistent respiratory tract disease. Our trial examined whether probiotics are able to prevent allergic sensitization and allergic asthma when given to 6-24 month old infants at an increased risk of allergies.


Description:

In our investigator-initiated prospective study, a total of 170 children with at least two episodes of wheezing and a first degree family history of atopic disease were recruited from our walk-in clinic between October 2002 and October 2004. We chose this relatively long period of time to exclude a seasonal selection bias (e.g., upper airway infections or airborne allergens). 131 eligible children (6 to 24 month old) were randomly assigned to a double-blind dietary supplementation with Lactobacillus rhamnosus strain GG ATCC 53103 (LGG) twice daily or placebo over six months. A computerized randomization schedule was prepared by a biostatistician with allocation and dispensing of capsules by the distributor of LGG. The capsules were matched for size, shape, and volume of content, which was reconstituted with 5 ml water and then given by spoon. Compliance was monitored by use of a capsule chart (completed by parents) and capsule counts. The parents were asked to keep a diary provided by the study group. Clinical monitoring was done for one year: before the intervention (visit 1), after 3, 6, 9, and 12 months (visit 2 to 5). It encompassed episodes of asthmatic exacerbations defined as cough and wheeze, numbers and days of associated hospitalizations, symptom free days, days without use of rescue medication (steroid suppositoria, a frequently used device in Western Europe), and associated inhalative steroid and beta-agonist use. Children underwent a physical examination including determination of the severity scoring of atopic dermatitis (SCORAD) index to assess eczema severity examination on each study visit to our walk-in clinic. To ensure consistency, the same investigator performed all SCORAD assessments. Atopic eczema was confirmed by characteristical cutaneous findings, pruritus, and chronic relapsing course. This last criterion was fulfilled if the child presented eczema for at least one month on at least one visit. Asthma diagnosis was based on an algorithm from an international paediatric asthma consensus group. Asthma was diagnosed if the child had chronic or recurrent cough, wheeze or shortness of breath, or both, and if other diagnosis were excluded and trial antiasthmatic treatment was effective. Blood samples were taken on visit 1, 3, and 5. Sensitization to common dietary and respiratory allergen was measured by total and antigen specific IgE assays against hen’s egg, cat epithelia, house dust mite (D1+2), birch pollen, milk protein, lactalbumin, timothy pollen, horse epithelia and alternaria by chemiluminescence-immunoassay. This highly-sensitive assay is suitable especially for the determination of low value of specific IgE. Additionally, eosinophilic cationic protein and eosinophils were determined.

Primary outcome measures were the asthma-related clinical events. Secondary measures were the serum concentrations of IgE, specific IgE, ECP, Eos, IL-2 soluble receptor alpha (IL-2Rα, to reflect T-cell related inflammatory state) and transforming growth factor beta (TGFβ, a profibrotic factor whose expression is increased in asthmatics, indicating airway remodeling. All parents supplied written informed consent prior to the study. Human experimentation guidelines of Good Clinical Practice, the German Drug Act and the declaration of Helsinki / Hong Kong were followed in the conduct of clinical research.


Recruitment information / eligibility

Status Completed
Enrollment 131
Est. completion date October 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 6 Months to 24 Months
Eligibility Inclusion Criteria:

- History of at least 3 episodes of wheezing bronchitis,

- First degree relative with history of allergic disease

Exclusion Criteria:

- Congenital malformations,

- Immunologic or oncologic systemic disorders,

- Current antibiotic therapy,

- Prior exposure to probiotics; and

- Known intolerances towards ingredients of the probiotics (LGG, microcristalline cellulose, gelatine, magnesiumstearate, titandioxide).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)


Locations

Country Name City State
Germany Childrens' Hospital, Goethe University Frankfurt Hessen

Sponsors (1)

Lead Sponsor Collaborator
Johann Wolfgang Goethe University Hospitals

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003 May 31;361(9372):1869-71. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary episodes of wheezing, drug use (inhalative steroids and betamimetics), hospital treatment October 2002 - October 2004
Secondary allergic sensitization, levels of IgE, inflammatory mediators, SCORAD indices October 2002-October 2004
See also
  Status Clinical Trial Phase
Completed NCT03850626 - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed NCT02911688 - Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure Phase 2
Active, not recruiting NCT01776177 - The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy N/A
Completed NCT00485576 - Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma Phase 2
Completed NCT00736801 - Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma N/A
Completed NCT00515775 - Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children N/A
Completed NCT04259164 - Anti-inflammatory Effects Glycopyrronium Phase 3
Active, not recruiting NCT04619017 - Airway Immune Response to Allergens (Use Lay Language Here) Phase 1
Completed NCT01699594 - Change in Airway Responsiveness After Allergen Exposure N/A
Completed NCT00999466 - The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen Phase 2
Completed NCT01353755 - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma Phase 3
Completed NCT00434434 - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma Phase 2
Completed NCT00492076 - Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Phase 4
Completed NCT00829179 - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Phase 3
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Recruiting NCT04109534 - Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma N/A
Active, not recruiting NCT05186025 - Tyrosine Allergoid Paediatric and Adult Study
Withdrawn NCT03307278 - House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance N/A
Enrolling by invitation NCT06151938 - Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
Withdrawn NCT04401631 - Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation